CHINA PHARMA HOLDINGS, INC.
CPHINYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M |
| Operating income | −$3.2M | −$4.6M | −$2.8M | −$3.5M | −$2.9M | −$2.6M |
| Net income | −$3.2M | −$4.7M | −$3.1M | −$4.0M | −$3.4M | −$2.9M |
| Total assets | $31.0M | $14.9M | $16.5M | $17.8M | $22.6M | $21.1M |
| Total liabilities | $8.3M | $7.1M | $9.0M | $13.5M | $16.6M | $13.1M |
| Equity | $22.7M | $7.7M | $7.5M | $4.3M | $6.0M | $8.0M |
| EPS (diluted) | $-0.74 | $-2.71 | $-0.91 | $-3.78 | $-0.74 | — |
| Shares out. | 32.6M | 14.8M | 8.5M | 47.3M | 45.6M | 43.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −78.2%
- Net margin
- −76.9%
- Return on equity
- −14.0%
- Return on assets
- −10.3%
- Return on capital (ROCE)
- −13.7%
- Liabilities / assets
- 26.6%
- Debt / equity
- 0.36×
- Book value / share
- $0.70
- Revenue growth (YoY)
- −8.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -3.85distress
- Accruals / assets
- −10.8%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2005
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2005
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2004
- NT 10-Kmissed a reporting deadline ↗Sep 27, 2004
- NT 10-Qmissed a reporting deadline ↗Feb 17, 2004
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Li ZhilinOfficer — CEO & Interim CFO | Sep 29, 2023 | Grant | 13.8M | $0.14 |
| Li ZhilinOfficer — CEO & Interim CFO | Sep 9, 2021 | Grant | 1.8M | $0.67 |
| Li ZhilinOfficer — CEO and interim CFO | Dec 23, 2020 | Grant | 2.0M | $0.00 |
| Waung FrankOfficer — Chief Financial Officer | Apr 28, 2012 | Grant | 100,000 | $0.00 |
| Li ZhilinOfficer — President and CEO | May 25, 2011 | Grant | 50,000 | $0.00 |
| Waung FrankOfficer — Chief Financial Officer | May 25, 2011 | Grant | 25,000 | $0.00 |
| Waung FrankOfficer — Chief Financial Officer | Dec 13, 2010 | Grant | 6,863 | $0.00 |
| Waung FrankOfficer — Chief Financial Officer | Nov 15, 2010 | Option exercise | 4,052 | — |
| Tsui Heung MeiDirector | Feb 9, 2010 | Grant | 1.5M | $3.00 |
| Tsui Heung MeiDirector | Nov 26, 2007 | Grant | 4.5M | $1.52 |
| Tsui Heung MeiDirector | Sep 13, 2006 | Grant | 10.0M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 121,426 | 1.0 | +1636.6% |
| Apr 30, 2026 | 6,992 | 1.0 | -10.3% |
| Apr 15, 2026 | 7,794 | 1.0 | -33.6% |
| Mar 31, 2026 | 11,735 | 1.0 | +28.1% |
| Mar 13, 2026 | 9,158 | 1.0 | -40.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity saleMar 3, 2026
- Entered a material agreement · Unregistered equity saleFeb 10, 2026
- Shareholder voteJan 6, 2026
- Entered a material agreement · Unregistered equity saleDec 23, 2025
- Entered a material agreement · Unregistered equity saleDec 10, 2025
- Regulation FD disclosureApr 4, 2025
- Terminated a material agreementDec 26, 2024
- Shareholder voteDec 26, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 15, 2026
- 10-KANNUAL REPORTApr 1, 2026
- NT 10-KNOTIFICATION OF LATE FILINGApr 1, 2026
- 8-KCURRENT REPORTMar 3, 2026
- 8-KCURRENT REPORTFeb 10, 2026
- 8-KCURRENT REPORTJan 6, 2026
- 8-KFORM 8-KDec 23, 2025
- 8-KCURRENT REPORTDec 10, 2025
- DEF 14ADEFINITIVE PROXY STATEMENTNov 14, 2025
- 10-QQUARTERLY REPORTNov 12, 2025
- PRE 14APRELIMINARY PROXY STATEMENTNov 4, 2025
- 10-QQUARTERLY REPORTAug 14, 2025
- 10-QQUARTERLY REPORTMay 14, 2025
- 8-KCURRENT REPORTApr 4, 2025
- 10-KANNUAL REPORTMar 31, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.